Every interventional clinical trial conducted in Sri Lanka has to clear a dual-track approval structure before it can start: product- and protocol-level authorization from the National Medicines Regulatory Authority (NMRA), and independent ethical clearance from an NMRA-recognized Ethics Review Committee (ERC). This guide walks through what the NMRA is, its legal basis, how the two tracks fit together, the mandatory public trial-registration step, and where sponsors should go to confirm current procedural detail rather than treat any single summary as final.
What the National Medicines Regulatory Authority Is
The NMRA is Sri Lanka’s national medicines regulatory authority, established under the National Medicines Regulatory Authority Act, No. 5 of 2015, and operating under Sri Lanka’s Ministry of Health. The NMRA states that it regulates clinical trials conducted in Sri Lanka to protect participant safety and to ensure the highest ethical standards are maintained, and it is the body responsible more broadly for the safety, efficacy, and quality of medicines and medical devices in the country. Because it controls the legal authority to import an investigational product and to authorize a trial protocol, the NMRA is the gate a sponsor cannot bypass: no investigational drug, biologic, vaccine, or device can lawfully be used in a Sri Lankan trial without NMRA authorization.
The Two-Track Structure: NMRA Review and Ethics Review Committee Clearance
Sri Lanka’s oversight structure separates product- and protocol-level regulatory review from human-subjects ethics review, the same basic architecture used across most jurisdictions with mature clinical trial systems (see the sibling guides on India’s CDSCO pathway and Pakistan’s DRAP pathway for how the equivalent split works elsewhere in South Asia):
- NMRA clinical trial authorization reviews the trial application, protocol, investigator’s brochure, product quality and manufacturing information, and import documentation. Published regulatory-affairs summaries describe this regulatory review as running through a Sub Committee on Clinical Trials (SCOCT) within the NMRA structure, reportedly with a particular focus on phase 2 and phase 3 studies; sponsors should confirm SCOCT’s current role and scope directly with the NMRA rather than treat committee-level detail as fixed, since this is not independently confirmed on the NMRA’s own published pages as of this writing.
- Ethics Review Committee (ERC) clearance is required from an ERC that is recognized/accredited under NMRA guidelines for the recognition of Ethics Review Committees. Sri Lanka has a number of institutional ERCs operating under this framework, along with sector-level accreditation coordinated through the Federation of Ethics Review Committees Sri Lanka (FERCSL). The Ethics Review Committee of the Sri Lanka Medical Association (SLMA), established in 1981, is Sri Lanka’s oldest institutional ERC and one of the more widely used committees for externally sponsored trials.
These two tracks are complementary, not substitutes for one another: NMRA authorization does not remove the need for a recognized ERC’s ethical clearance, and ERC clearance does not remove the need for NMRA authorization of the investigational product and protocol. Sponsors planning a Sri Lankan site should budget for both tracks from the same start date, since ethics clearance is generally expected to be in place before, or in parallel with, the NMRA regulatory submission.
The NMRA Clinical Trial Approval Pathway
The NMRA has published dedicated clinical trial guidance, currently Guideline for the Conduct of Clinical Trials in Sri Lanka, Version 5.0, along with supplementary guidance covering non-routine/emergency processing and safety reporting. At a minimum, sponsors preparing a submission should expect the NMRA to require a completed clinical trial (CT) application form, the trial protocol and investigator’s brochure, product quality/manufacturing documentation, supplementary information supporting importation of medicine, medical device, or borderline-product samples, and evidence that ethics review has been initiated or completed, consistent with the dual-track structure above. Bioavailability/bioequivalence (BA/BE) centre approvals follow a separate, annex-listed document set under the same guideline.
This guide deliberately does not state specific submission fees or fixed review-timeline commitments as settled fact: NMRA guidelines, fee schedules, and application checklists are revised periodically (the current guideline is already at its fifth major revision), and a sponsor should confirm current requirements directly against the NMRA’s own published clinical trials guidance before finalizing a submission timeline, rather than relying on a third-party summary that may lag a revision.
Mandatory Trial Registration: the Sri Lanka Clinical Trials Registry (SLCTR)
Sri Lanka has operated its own prospective trials registry, the Sri Lanka Clinical Trials Registry (SLCTR), since November 2006, making it the first functioning clinical trials registry in South Asia. The SLCTR was recognized as a Primary Registry within the WHO International Clinical Trials Registry Platform (WHO-ICTRP) Registry Network in March 2008, the fourth primary registry to join that network, and it is designed to meet both the WHO-ICTRP minimum data set and ICMJE trial-registration expectations. Registration on a WHO-ICTRP primary registry (which the SLCTR satisfies for Sri Lanka-based trials) is expected before enrolling the first participant, consistent with the general international norm that trials be registered prospectively rather than retrospectively. In addition to the core WHO data set, the SLCTR records ethics review committee approval status and solicits periodic progress reports from investigators, which sponsors should factor into ongoing trial-management obligations rather than treating registration as a one-time filing.
Good Clinical Practice Expectations
As with most national regulators overseeing clinical trials, Sri Lanka’s framework references Good Clinical Practice (GCP) standards consistent with ICH guidance, and expects proper informed consent procedures throughout, documented via an informed consent form (ICF). Sponsors already operating GCP-aligned quality-management systems for other jurisdictions should expect the same core expectations to apply in Sri Lanka: qualified investigators, a documented informed-consent process, adverse-event and safety reporting to the NMRA, and inspection readiness.
How This Differs from Neighboring South Asian Pathways
Sri Lanka’s structure, a national medicines regulator (NMRA) operating alongside, and in coordination with, an independently accredited ethics-committee system, is broadly similar in shape to the frameworks used elsewhere in South Asia, including India’s Central Drugs Standard Control Organisation (CDSCO), Pakistan’s Drug Regulatory Authority (DRAP), and Bangladesh’s Directorate General of Drug Administration (DGDA). None of these systems are interchangeable: approval from one country’s regulator or ethics body does not carry over to another, and each requires an independent national submission, its own document set, and its own timeline. Sponsors running multi-country South Asian trials should treat Sri Lanka, India, Pakistan, and Bangladesh as four fully separate regulatory dossiers rather than a single regional filing, and should budget separately for each country’s trial-registry obligations as well.
Frequently Asked Questions
Which body approves clinical trials in Sri Lanka?
The National Medicines Regulatory Authority (NMRA), established under the National Medicines Regulatory Authority Act, No. 5 of 2015, authorizes the clinical trial protocol and the import of investigational products. A separate ethical clearance from an NMRA-recognized Ethics Review Committee (ERC) is required in addition to NMRA authorization.
Is ERC approval the same as NMRA approval?
No. An NMRA-recognized Ethics Review Committee reviews the ethical acceptability of the research, including informed consent materials and participant protections; the NMRA reviews and authorizes the regulatory, protocol, and product-import elements of the trial. Both are required, and they are generally pursued in parallel or with ethics clearance in place before final NMRA authorization.
Do clinical trials in Sri Lanka need to be registered in a public registry?
Yes. Trials should be registered on a WHO-ICTRP primary registry before enrolling the first participant; the Sri Lanka Clinical Trials Registry (SLCTR), operating since 2006 and recognized as a WHO-ICTRP primary registry since March 2008, is the registry built specifically for this purpose and also records ethics-approval status and progress reports.
What is SCOCT?
SCOCT (the Sub Committee on Clinical Trials) is described in published regulatory-affairs summaries as the NMRA body handling clinical trial application review, reportedly with particular involvement in phase 2 and phase 3 studies. Because this level of internal committee detail is not independently confirmed on the NMRA’s own published pages as of this writing, sponsors should verify SCOCT’s current role directly with the NMRA rather than rely solely on third-party summaries.
What guideline governs clinical trial conduct in Sri Lanka?
The NMRA’s Guideline for the Conduct of Clinical Trials in Sri Lanka, currently Version 5.0, is the primary operational guidance, supplemented by separate NMRA guidance on ethics review committee recognition, non-routine/emergency processing, and safety reporting. Sponsors should confirm they are working from the current version before submission, since the guideline has already gone through multiple revisions.
This guide summarizes publicly available NMRA and SLCTR guidance current as of this writing. The NMRA periodically revises application checklists, fees, committee structures, and stated timelines; sponsors and research administrators should confirm current requirements directly against the NMRA’s and SLCTR’s own published guidance before building a submission plan.
